-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Downgrades Entrada Therapeutics to Neutral

Benzinga·05/08/2026 11:57:30
Listen to the news
HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Entrada Therapeutics (NASDAQ:TRDA) from Buy to Neutral.